How we treat elderly patients with Hodgkin lymphoma

Current Opinion in Oncology

Volumn 23, Issue 5, 2011, Pages 421-428

  Björkholm, Magnus ^a   Svedmyr, Erik ^a   Sjöberg, Jan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Elderly; epidemiology; Hodgkin lymphoma; prognosis; treatment

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IFOSFAMIDE; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; MITOGUAZONE; MITOXANTRONE; MOCETINOSTAT; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ASPIRATION BIOPSY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMORBIDITY; DIABETES MELLITUS; DISEASE FREE SURVIVAL; DRUG TOLERABILITY; ELDERLY CARE; FRAIL ELDERLY; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HYPERTENSION; IMMUNOPHENOTYPING; LABORATORY TEST; LIFE EXPECTANCY; LUNG TOXICITY; MORBIDITY; MULTIPLE CYCLE TREATMENT; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; REVIEW; TREATMENT OUTCOME; TUMOR BIOPSY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HODGKIN DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS;

EID: 80052008584     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328348c6c1     Document Type: Review

References (43)

1. Armitage JO. Early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363: 653-662.
2. Borchmann P, Engert A. The past: what we have learned in the last decade. Hematology Am Soc Hematol Educ Program 2010; 2010:101-107.
3. Bartlett NL. The present: optimizing therapy-too much or too little? Hematology Am Soc Hematol Educ Program 2010; 2010:108-114.
4. Sjoberg J, Halthur C, Kristinsson SY, et al. Improved patient survival and cure for Hodgkin lymphoma: a population-based study of 6,136 patients diagnosed in Sweden 1973-2005. ASH Annual Meeting and Exposition 2009; Abstract No. 1553.
5. Hjalgrim H, Askling J, Pukkala E, et al. Incidence of Hodgkin's disease in Nordic countries. Lancet 2001; 358:297-298. (Pubitemid 32738971)
6. Evens AM, Sweetenham JW, Horning SJ. Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology (Williston Park) 2008; 22:1369-1379.
7. Klimm B, Diehl V, Engert A. Hodgkin's lymphoma in the elderly: a different disease in patients over 60. Oncology (Williston Park) 2007; 21:982-990. (Pubitemid 47106312)
8. Engert A, Ballova V, Haverkamp H, et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 2005; 23:5052-5060. (Pubitemid 46224012)
9. Landgren O, Porwit MacDonald A, Tani E, et al. A prospective comparison of fine-needle aspiration cytology and histopathology in the diagnosis and classification of lymphomas. Hematol J 2004; 5:69-76. (Pubitemid 38262793)
10. Wotherspoon AC, Norton AJ, Lees WR, et al. Diagnostic fine needle core biopsy of deep lymph nodes for the diagnosis of lymphoma in patients unfit for surgery. J Pathol 1989; 158:115-121. (Pubitemid 19157013)
11. Van Spronsen DJ, Janssen-Heijnen ML, Lemmens VE, et al. Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. Eur J Cancer 2005; 41:1051-1057. (Pubitemid 40602858)
12. Jarrett RF. Risk factors for Hodgkin's lymphoma by EBV status and significance of detection of EBV genomes in serum of patients with EBV-associated Hodgkin's lymphoma. Leuk Lymphoma 2003; 44 (Suppl 3):S27-S32.
13. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506-1514. (Pubitemid 28543499)
14. Proctor SJ, Wilkinson J, Sieniawski M. Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future. Crit Rev Oncol Hematol 2009; 71:222-232.
15. Bjorkholm M, Axdorph U, Grimfors G, et al. Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trial. Ann Oncol 1995; 6:895-899.
16. Landgren O, Pfeiffer RM, Kristinsson SY, Bjorkholm M. Survival patterns in patients with Hodgkin's lymphoma with a preexisting hospital discharge diagnosis of autoimmune disease. J Clin Oncol 2010; 28:5081-5087.
17. Bjorkholm M, Wedelin C, Holm G, Essy-Ehsing B. Familial longevity and prognosis in Hodgkin's disease. Cancer 1984; 54:1088-1092. (Pubitemid 14069830)
18. Landgren O, Algernon C, Axdorph U, et al. Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 2003; 88:438-444. (Pubitemid 36547130)
19. Levis A, Depaoli L, Urgesi A, et al. Probability of cure in elderly Hodgkin's disease patients. Haematologica 1994; 79:46-54.
20. Hodgkingruppen S. Nationella riktlinjer fö r utredning och behandling av Hodgkins lymfom. 2010. http://www.roc.se/lymfom/vardprogram/nat- riktlin-HL-100611.pdf [Accessed 11 June 2010].
21. Josting A. Prognostic factors in Hodgkin lymphoma. Expert Rev Hematol 2010; 3:583-592.
22. Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005; 23:7614-7620. (Pubitemid 46291825)
23. Graczyk J, Cheung M, Buckstein R, Chan K. G-CSF as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a decision analysis. ASH Annual Meeting and Exposition 2010.
24. Kalin M, Kristinsson SY, Cherif H, et al. Fatal Pneumocystis jirovecii pneumonia in ABVD-treated Hodgkin lymphoma patients. Ann Hematol 2010; 89:523-525.
25. Bö ll B, Gö rgen H, Fuchs M, et al. Feasibility and efficacy of ABVD in elderly Hodgkin lymphoma patients: analysis of two randomized prospective multicenter trials of the German Hodgkin study group (HD10 and HD11). ASH Annual Meeting and Exposition 2010; Abstract No. 418.
26. Bjorkholm M. How much chemotherapy in advanced Hodgkin's disease? Ann Oncol 1997; 8:1281-1283. (Pubitemid 28164088)
27. Carde P, Koscielny S, Franklin J, et al. Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? Ann Oncol 2002; 13 (Suppl 1):86-91. (Pubitemid 34567408)
28. Kolstad A, Nome O, Delabie J, et al. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. Leuk Lymphoma 2007; 48:570-576. (Pubitemid 46487767)
29. Osby E, Hagberg H, Kvaloy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003; 101:3840-3848. (Pubitemid 36857855)
30. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363: 640-652.
31. Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood 2010; 116:5103-5110.
32. Levis A, Anselmo AP, Ambrosetti A, et al. VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol 2004; 15:123-128. (Pubitemid 38139613)
33. Bö ll B, Halbsguth T, Gö rgen H, et al. PVAG (Prednisone, Vinblastine, Doxorubicin and Gemcitabine) in elderly patients with intermediate or advanced stage Hodgkin lymphoma: Final Results of a Phase II Study of the German Hodgkin Study Group (GHSG) ASH Annual Meeting and Exposition 2010. 2010; Abstract No. 2827.
34. Fanale MA, Younes A. Nodular lymphocyte predominant Hodgkin's lymphoma. Cancer Treat Res 2008; 142:367-381.
35. Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2009; 2009:497-506.
36. Borchmann P, Mü ller H, Brillant C, et al. Longitudinal evaluation of quality of life and fatigue in Hodgkin lymphoma patients. ASH Annual Meeting and Exposition 2010. 2010; Abstract No. 935.
37. Blum KA. Upcoming diagnostic and therapeutic developments in classical Hodgkin's lymphoma. Hematology Am Soc Hematol Educ Program 2010; 2010:93-100.
38. Boll B, Borchmann P, Diehl V. Emerging drugs for Hodgkin's lymphoma. Expert Opin Emerg Drugs 2010; 15:585-595.
39. Chen R, Gopal AK, Smith SE, et al. Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma. ASH Annual Meeting and Exposition 2010. 2010; Abstract No. 283.
40. Younes A, Bociek RG, Kuruvilla J, et al. Mocetinostat (MGCD0103), an isotype-selective histone deacetylase (HDAC) inhibitor, produces clinical responses in relapsed/refractory Hodgkin lymphoma (HL): Update From a Phase II Clinical Study. ASH Annual Meeting and Exposition 2010. 2010; Abstract No. 1763.
41. Johnston PB, Inwards DJ, Colgan JP, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010; 85:320-324.
42. Boll B, Fuchs M, Reiners KS, et al. Lenalidomide in patients with relapsed or refractory Hodgkin lymphoma. ASH Annual Meeting Abstracts. 2010; 116:2828.
43. Walewski J, Paszkiewicz-Kozik E, Borsaru G, et al. Resminostat in relapsed or refractory Hodgkin lymphoma: initial results of the SAPHIRE phase II trial with a novel oral histone deacetylase (HDAC) inhibitor. ASH Annual Meeting and Exposition 2010. 2010; Abstract No. 2811.